Navigation Links
Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases
Date:11/6/2007

ngal infections, herpes, influenza, malaria, meningitis, pneumonia, respiratory infections, rotavirus, sepsis, smallpox, and urinary tract infections, among others.

To view the report and other information about medicines in development for infectious diseases, go to: http://www.phrma.org/

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $43 billion in 2006 in discovering and developing new medicines. Industry wide research and investment reached a record $55.2 billion in 2006.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://innovation.org/

For information on the Partnership for Prescription Assistance, visit: https://www.pparx.org/Intro.php

For information on the danger of imported drugs, visit: http://buysafedrugs.info/


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2008)...tudy finds the majority of acute lymphoblastic leu...ent at the time of diagnosis , , MEMPHIS, T...s at St. Jude Children,s Research Hospital have id... cells of children with acute lymphoblastic leukem...pathway to designing treatments for ALL relapse in...
(Date:11/26/2008)... Expanded to 406 Subjects , , FRANKLIN, Mas...Inc. (OTC Bulletin Board: PLCSF) announced today t...od and Drug Administration (FDA) for its U.S. pivo...y,s RenalGuard System(TM) and associated therapy ...(CIN). , , The FDA also approved PLC,s requ...
(Date:11/25/2008)...ts reveal most respondents against expanding stati... , LITTLE FALLS, N.J., Nov. 25 ...may lower the cardiovascular risk of healthy patie... statin use in older adults, according to a nation...12 participants took part in the online poll condu...
(Date:11/25/2008)...VALE, Calif., Nov. 25 Ph...ed that the company has completed a Phase 1,clini...st-in-class,small-molecule Factor VIIa inhibitor....volunteers to evaluate the safety and pharmacologi... PCI-27483 resulted in a linear dose,response in ...
Breaking Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Study shows autism symptoms can improve into adulthood 2104 1Study shows autism symptoms can improve into adulthood 2104 2Possible safer target for anti clotting drugs found 2102 1Possible safer target for anti clotting drugs found 2102 2Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals 2100 1Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals 2100 2Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals 2100 3AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care 2098 1AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care 2098 2
...is of Phase III trial data underlines M6G,s,benefi...erative,pain , CAMBRIDGE, England, 7th March 2007 ...dge based biopharmaceutical company today,announce... (M6G022),of M6G (morphine-6-glucuronide) in over ...nary data released on 20th February,showed that M6...
...ility of Higher Doses to Further Reduce Antibodies... /PRNewswire-FirstCall/ -- La Jolla,Pharmaceutical...,results from its ongoing double-blind, placebo-co...betimus sodium), its drug,candidate for systemic l... interim antibody data indicate that patients trea...
Other Medicine Technology:CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 2CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 3CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 4CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 5CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 6CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G 7La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 7
(Date:12/1/2008)... a cold December day in,Memphis, Tennessee and Fe...amilo Villegas and LPGA star Morgan Pressel have g...s that has brought three of the biggest names in,...e important than any game of,golf -- children bat...m.com/cgi-bin/prnh/20081201/CLM117 ) , Sin...
(Date:12/1/2008)...d Over Prior Year Quarter --, -- Fully I... and Sharpened Commercial Fo... , RICHMOND, BC, Dec. 1 /PRNewswire-FirstCall/...lar device company, today announced financial resu...ptember 30, 2008. , Neovasc Chief Executive Off...
(Date:12/1/2008)...ene repressors for anticancer therapy , Michel...ing Cancer Center, New York, have developed a new ...herapeutic purposes, and used this to mediate effe...ding RNA molecules known as miRNAs are powerful na... the miRNA miR-181a was harnessed to segregate exp...
(Date:12/1/2008)... ViroPharma Incorporated,(Nasdaq: VPHM ) today ...l,Biologics License Application (sBLA) to the U.S...TM) C1 Inhibitor (human) as a treatment for acute ...The sBLA is based on a re-analysis and resubmissio...study of Cinryze and interim data from an ongoing ...
Breaking Medicine News(10 mins):Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 2Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 3Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 4Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 5Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 6Health News:More than 1,500 Eagles -- Each One with a Story: Eagles Made During PGA TOUR and LPGA Season Result in Record Donation to St. Jude 7Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 2Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 3Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 4Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 5Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 6Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 7Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 8Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 9Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 10Health News:Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 11Health News:JCI online early table of contents: Dec. 1, 2008 2Health News:JCI online early table of contents: Dec. 1, 2008 3Health News:JCI online early table of contents: Dec. 1, 2008 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5
... even after they stop smoking, says a new study, c...ase ceases when smoking ceases . The new finding i...ease with bronchial inflammation, it will continue...moking. This comes from an international team of ...
...sia's largest healthcare groups, Tuesday launched ...ty in Asia . Going beyond the realm of curative c...cility offering solutions across the healthcare sp...ic medicine, research, information technology and ...
...i generic medicines group Teva to resume deliverie...t by Novartis, the Swiss pharmaceutical group said...ey rejected on Monday a request from Novartis to s...of generic versions of the drug, pending a trial i...
...at has helped thousands of disabled worldwide to w...s first centre on foreign soil . The Colombian gov...g Sahayata Samiti (BMVSS), producers of the artifi...th American country. The BMVSS has entered into a ...
Other Medicine News:Health News:Apollo Sets Up Asia's First Health City in Hyderabad 2Health News:Jaipur Foot All Set to Launch Its Centre in Columbia 2
...ange of miniTHERM incubators is available, ensurin...n solution for their specific requirements. miniTH...ompact and extremely space saving. Their size corr... It is possible to stack up to three units on top ...
In microbiological laboratories and for in vitro fertilization, as well as in cancer research or tissue engineering, the Heraeus CO2 incubator BBD 6220 provides the best contamination protection and
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc.
US Autoflow Single Chamber Stackable Water-Jacketed CO2/O2 Inc.
Medicine Products: